secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0000950170-23-013276
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics announces ulcerative colitis trial for CP101, amends UMN license
--------------------------------------------------------------------------------

- Investigator-sponsored trial at Brigham and Women's Hospital comparing two doses of CP101 in mild-to-moderate ulcerative colitis; topline data expected in 2025.
- Amendment to University of Minnesota license allows Finch to satisfy performance milestones via sublicensing, aligning with new partnership-focused strategy.
- Finch exclusively licenses 13 issued patents and 7 patent applications covering human fecal microbe formulations and microbiota diversity methods.
- Clinical trial designed to generate data on safety, PK, PD, and clinical efficacy, building on microbiome evidence in ulcerative colitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/0000950170-23-013276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/fnch-20230412.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer